Patient Registry of Outcomes in Spasticity Care

The document reports on a prospective, observational study involving 487 patients with stroke and traumatic brain injury, treated for spasticity with chemodenervation or neurolysis using onabotulinumtoxinA or phenol. The study, conducted across multiple centers with 17 physicians, aimed to characterize clinical and patient-reported outcomes. The most common treatment areas were the flexed wrist in the upper limb and the equinovarus-equinus foot in the lower limb. The study found significant improvements in Ashworth scores (P<.0001) and pain reduction, particularly in the foot with a score decrease of -4.2±3.4. Patient satisfaction was high, with 78.0% satisfied with their overall treatment and significant progress reported towards primary (74.1%) and secondary (67.6%) goals. No significant adverse effects were related to the treatments. The data suggests dosing differences for commonly treated patterns of upper motor neuron (UMN) dysfunction and muscles, and the findings can assist clinicians in managing spasticity in patients.